中
Home
About TUL
Group Introduction
Executive Directors
Subsidiaries
Contact Us
Innovation in R&D
R&D Pipeline
R&D Platform
R&D Updates
News
TUL Highlights
Product Center
Finished Products
Comprehensive Health Products
APIs and Intermediates
Animal protection products
Empty capsule
Medical device
Cosmetic Peptide Series
Sustainability
Enhancing Governance
Normalizing Healthiness
Brand Building
People-Oriented
Green Development
ESG Reports
ESG News
Investor Relations
News
TUL Highlights
2026-07-15
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT SODIUM HYALURONATE EYE DROPS WITH NEW SPECIFICATION
Learn More
2026-07-03
APPROVAL FOR MARKETING OF THE GROUP’S PRODUCT TADALAFIL TABLETS
Learn More
2026-06-22
Tsoi Hoi Shan Attended Novo Nordisk Roundtable to Discuss the Global Impact of Chinese Innovation
Learn More
2026-06-12
APPROVAL FOR CLINICAL TRIAL OF THE GROUP’S PRODUCT TUL321 CAPSULES
Learn More
2026-05-20
APPROVAL FOR CLINICAL TRIAL OF GROUP’S PRODUCT TUL108 FOR INJECTION
Learn More
All News
Select Year
2026
2025
2024
ESG Report 2025
2026-04-30
FDA APPROVAL OF IND FOR GROUP’S PRODUCT TUL321 CAPSULES
2026-04-29
APPROVAL FOR CLINICAL TRIAL OF THE GROUP’S PRODUCT DUPILUMAB INJECTION
2026-04-23
The United Laboratories International Holdings Limited Announces 2025 Annual Results
2026-03-26
Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
2026-03-26
APPROVAL FOR MARKETING OF THE GROUP'S PRODUCT INSULIN DEGLUDEC INJECTION
2026-03-10
Zhuhai United Laboratories Trading Co., Ltd. Won the Title of "Quality Management Advanced Enterprise" in Zhuhai Pharmaceutical Industry for 2025
2026-03-07
The United Animal Healthcare (Inner Mongolia) Co., Ltd. Reached Strategic Cooperation with Lanzhou Institute of Husbandry and Pharmaceutical Sciences of CAAS
2026-03-04
Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
2026-02-25
Prev
1
2
3
4
5
...
17
Next
WeChat
Official
Account
To Top